Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
  • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
  • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
  • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
  • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
  • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
  • A61K9/7061—Polyacrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
  • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
  • A61K31/728—Hyaluronic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics

Definitions

• the present invention refers to a plaster in the form of a thin film for the treatment of slight psoriasis, allergic dermatitis, and dermatosis.
• Corticosteroids are amply used in cases of eczema, dermatitis, contact dermatitis, psoriasis, etc., being remarkably efficacious for the treatment of skin diseases.
• prolonged treatments with said drugs cause untoward side effects at a systemic level, such as for example the suppression of the adrenocortical pituitary function, a phenomenon taking place even when corticosteroids are for external use and administered locally.
• a formulation containing corticosteroids in a low concentration to be administered locally does not secure a sufficient therapeutic effect on said diseases of the immune system.
• An approach to increase the corticosteroid percutaneous absorption consisted in the use of said active ingredient in a therapeutic formulation for local use containing a percutaneous absorption promoter, such as urea, propylene glycol, etc.
• said adhesive plaster characterized by having a very low thickness , lower than 500 ⁇ m, comprises:
• the adhesive plaster according to the present invention preferably contains both active ingredients in the adhesive layer.
• Betamethasone is present in the adhesive plaster according to the present invention as betamethasone valerate; the hyaluronic acid preferably has a molecular weight ranging from 30,000 to 1,200,000, and more preferably from 30,000 to 300,000, and is preferably present as sodium salt.
• the adhesive plaster being the object of the present invention is generally 200 to 500 ⁇ m thick and preferably 250 to 480 ⁇ m thick.
• the support outer layer is a film made of a polymeric material preferably selected from a group comprising polyethylene, ethylene-methyl methacrylate copolymer, polypropylene; the support inner layer is made of woven or non-woven fabric, preferably selected from the group comprising polyethylene, polypropylene, rayon.
• Adhesive layer (b) contains an adhesive hydrogel matrix comprising polyacrylic acid in an aqueous dispersion, with a polyacrylic acid concentration ranging from 0.1 to 9% by weight in respect of the adhesive layer total weight.
• the aqueous dispersion used is as found in commerce under the trademark AC10H®; its viscosity ranges from 10,000 to 50,000 mPa.s. and its polyacrylic acid content is in a concentration of 20% by weight.
• the aforesaid aqueous dispersion is added in concentrations ranging from 10 to 30% by weight, and preferably in a concentration of 20% by weight, in respect of the adhesive layer total weight.
• the adhesive plaster adhesive layer preferably weighs 150 to 400 m 2 /g and is 120 to 280 ⁇ m thick.
• the adhesive layer contains betamethasone valerate in a concentration of 0.05 to 5% by weight, and more preferably of 0.1% by weight in respect of the adhesive layer total weight, and sodium hyaluronate in a concentration of 0.1% to 3% by weight and still more preferably of 0.2% by weight in respect of the adhesive layer total weight.
• the adhesive layer may contain excipients selected from preservatives, wetting agents, thickeners, cross-linking agents, pH adjusters, stabilisers, etc., and mixtures thereof.
• the thickeners preferably used are sodium polyacrylate having a molecular weight of 450,000 to 4,000,000, polyacrylic acid having a molecular weight of 450,000 to 4,000,000, sodium carboxymethylcellulose or mixtures of said thickeners.
• the preservatives preferably used are methylparaben, propylparaben, and more preferably mixtures of the said preservatives.
• the cross-linking agent is preferably dihydroxyaluminium amino acetate.
• the wetting agent is preferably selected from the group comprising glycerol, butylene glycol, propylene glycol or mixtures thereof.
• the stabiliser is preferably sodium edetate; the pH adjuster is preferably tartaric acid.
• the adhesive plaster according to the present invention is prepared on the basis of the following method.
• the hydrocolloidal matrix is co-extruded between the support film and the protective plastic film to be removed immediately prior to use.
• the preparation of the adhesive plaster according to the invention is reported in the following examples, conveyed by way of indication.
• the adhesive matrix was prepared by mixing the components in a turbomixer and co-extruded between the two layers (support and protective layers). The sandwich obtained was cut to the desired size, so that the adhesive layer of each adhesive plaster would contain the components shown in the following table Components % by weight Mg/adhesive plaster Betamethasone valerate 0.1 1.5 Sodium hyaluronate - - Methylparaben 0.1 1.5 Propylparaben 0.05 0.75 Butylene glycol 3.00 45.00 Glycerol 39.00 585.00 Polyacrylic acid 1.0 15.00 20% Polyacrylic acid aqueous dispersion 20.00 300.00 Sodium polyacrylate 4.00 60.00 Sodium carboxymethylcellulose 4.60 69.00 Hydroxypropyl methylcellulose 0.50 7.50 Dihydroxyaluminium amino acetate 0.06 0.90 Disodium edetate 0.07 1.05 Tartaric acid 1.50 22.50 Water Balance to 100 390.30 or as reported in the following table: Components % by weight mg/adhe
• Example 1B Adhesive layer application to the support material
• composition was applied to the support weighing 225 mg and 75 ⁇ m thick by co-extrusion to obtain an adhesive plaster 280 ⁇ m thick and weighing, without the removable film, 1.5 g.
• Example 1C The protective polyethylene terephthalate film 75 ⁇ m thick was applied.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Dermatology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Inorganic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Molecular Biology (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Materials For Medical Uses (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Publications (3)

Family

ID=11382159

Family Applications (1)

Country Status (12)

Families Citing this family (12)

Family Cites Families (10)

• 1999
  • 1999-03-05 IT IT1999MI000449A patent/IT1309588B1/it active
  • 1999-10-22 US US09/425,475 patent/US6379695B1/en not_active Expired - Lifetime
  • 1999-11-02 CA CA002288482A patent/CA2288482C/en not_active Expired - Lifetime
• 2000
  • 2000-01-10 HU HU0000045A patent/HU225599B1/hu unknown
  • 2000-01-11 CZ CZ200098A patent/CZ295714B6/cs not_active IP Right Cessation
  • 2000-01-13 SK SK40-2000A patent/SK284668B6/sk not_active IP Right Cessation
  • 2000-02-04 PT PT00102430T patent/PT1034780E/pt unknown
  • 2000-02-04 AT AT00102430T patent/ATE269697T1/de active
  • 2000-02-04 DE DE60011686T patent/DE60011686T2/de not_active Expired - Lifetime
  • 2000-02-04 EP EP00102430A patent/EP1034780B1/en not_active Expired - Lifetime
  • 2000-02-04 DK DK00102430T patent/DK1034780T3/da active
  • 2000-02-04 ES ES00102430T patent/ES2222860T3/es not_active Expired - Lifetime

Also Published As

Similar Documents

Legal Events